myeloma patient Articles
-
Clinician Attitudes are Shifting on MRD-guided Decision Making in Multiple Myeloma
This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). In the years following, researchers have explored the value of using MRD status to guide treatment in blood cancers – and the mounting ...
-
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system ...
-
Tackling Barriers to MRD Adoption in the Community Setting
The day a person receives a cancer diagnosis is likely one of the worst days of their lives. For some new patients, the typical approach may be to seek care from a specialist at an NCCN-designated cancer center. But for the majority of Americans, it will be a community oncologist who guides them through their cancer journey. That’s why Adaptive recently partnered as a sponsor with ...
-
Possible treatment of human multiple myeloma found
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka University in Japan have discovered the CD98 heavy chain, a common ...
By Profacgen
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you